{"schema_version":"1","generated_at":"2026-10-28T09:29:52.495Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/donald-richards","json_url":"https://www.findmykol.com/kol/donald-richards/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"donald-richards","name":"Donald Richards","credential":"MD","title":"Medical Oncology, Hematology (specialty line on profile)","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Gastrointestinal","therapeutic_areas":["Gastrointestinal","Lung"],"institution":"Texas Oncology-Tyler","institution_url":"https://www.findmykol.com/institution/texas-oncology-tyler","city":"Tyler","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1659313559"},"summary":"Donald Richards is Medical Oncology, Hematology (specialty line on profile) at Texas Oncology-Tyler. ClinicalTrials.gov lists 8 registered studies with this person as an investigator.","overview":{"text":"Donald Richards, MD, is Medical Oncology, Hematology (specialty line on profile) at Texas Oncology-Tyler. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 33 companies.","bullets":["Top research focus: Gastroesophageal Cancer","8 registered trials on ClinicalTrials.gov","Open Payments reporting from 33 companies"],"generated_at":"2026-10-27"},"focus":{"indications":[{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Small Cell Lung Carcinoma","therapeutic_area":"Oncology","trials":3,"topics":0,"strength":9},{"label":"Neoplasm Metastasis","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Stomach Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Rectal Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Bladder / Urothelial Cancer","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Carcinoma, Transitional Cell","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3}],"research_topics":["Gastroesophageal Cancer","Lung Cancer (NSCLC/SCLC)","Small Cell Lung Carcinoma","Stomach Neoplasms"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Epkinly","generic":"Epcoritamab","trials":0,"payments":18,"publications":0,"mentions":18},{"name":"Imbruvica","generic":"Ibrutinib","trials":0,"payments":15,"publications":0,"mentions":15},{"name":"Lorbrena","generic":"Lorlatinib","trials":0,"payments":7,"publications":0,"mentions":7}]},"works_with":{"total":30,"shown":3,"withheld":27,"rows":[{"name":"Abbvie Inc.","trials":0,"payments":14,"mentions":14},{"name":"Tempus AI, Inc","trials":0,"payments":14,"mentions":14},{"name":"Pharmacyclics LLC, An AbbVie Company","trials":0,"payments":9,"mentions":9}]}},"scholarship":{"h_index":0,"pubmed_count":0,"latest_activity_year":2025,"source":"works"},"trials":{"count":8,"shown":3,"withheld":5,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07218380","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"Eli Lilly and Company","source_url":"https://clinicaltrials.gov/study/NCT07218380","trial_url":"https://www.findmykol.com/trial/NCT07218380"},{"nct":"NCT06069570","title":"Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"Kiromic BioPharma Inc.","source_url":"https://clinicaltrials.gov/study/NCT06069570","trial_url":"https://www.findmykol.com/trial/NCT06069570"},{"nct":"NCT05703971","title":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Genprex, Inc.","source_url":"https://clinicaltrials.gov/study/NCT05703971","trial_url":"https://www.findmykol.com/trial/NCT05703971"}],"source":"trials"},"payments":{"company_count":33,"program_years":{"first":2021,"last":2025},"rows_total":48,"shown":3,"withheld":45,"rows":[{"payer":"Janssen Global Services, LLC","program_year":2025,"amount_usd":1980,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659313559"},{"payer":"Galvanize Therapeutics, Inc","program_year":2025,"amount_usd":144.41,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659313559"},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":109.57,"payment_count":5,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659313559"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1659313559","source":"payments"},"prescribing":{"data_year":2024,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":48.5,"classes_total":13,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":21.3,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":28},{"class":"Microtubule Inhibitor","setting":"administered","share_pct":14.9,"drugs":[{"name":"Paclitaxel","share_pct":100}],"max_beneficiaries":33}]},{"area":"Blood & clotting","share_pct":22.5,"classes_total":4,"classes":[{"class":"Parenteral Iron Replacement","setting":"administered","share_pct":12.6,"drugs":[{"name":"Iron sucrose","share_pct":100}],"max_beneficiaries":21},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":9.8,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":13}]},{"area":"Metabolism & gastrointestinal","share_pct":14.8,"classes_total":5,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":11.7,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":30},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":2.6,"drugs":[{"name":"Palonosetron hcl","share_pct":56.9},{"name":"Granisetron hydrochloride","share_pct":38.5},{"name":"Ondansetron Odt","share_pct":3.1},{"name":"Ondansetron Hcl","share_pct":1.4}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":0,"shown":0,"withheld":0,"recent":[],"source":"works"},"presence":{"mentions":{"total":1,"shown":1,"rows":[{"url":"https://www.texasoncology.com/doctors/donald-richards","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":3,"shown":3,"rows":[{"value":"M.D. (medical doctorate), University of Texas Health Science Center, San Antonio","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"},{"value":"Ph.D. in Cell Biology, Baylor College of Medicine","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"},{"value":"Board certified in medical oncology","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"}]},"roles":{"total":6,"shown":3,"rows":[{"value":"Member, GI Cancer Committee, The US Oncology Network","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"},{"value":"Member, Translational Oncology Program, The US Oncology Network","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"},{"value":"Member, Pancreatic Cancer Research Team","source_url":"https://www.texasoncology.com/doctors/donald-richards","status":"verified","collected_at":"2026-10-27"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"Christus Mother Frances Hospital (Tyler)","source_url":"https://medifind.com/doctors/donald-richards/10903744","status":"provisional","collected_at":"2026-10-27"}]}},"similar":[{"name":"Eric Van Cutsem","slug":"eric-cutsem","institution":"University Hospitals Leuven (UZ Leuven)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/eric-cutsem","json_url":"https://www.findmykol.com/kol/eric-cutsem/profile.json"},{"name":"Josep Tabernero","slug":"josep-tabernero","institution":"Vall d'Hebron Institute of Oncology (VHIO)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/josep-tabernero","json_url":"https://www.findmykol.com/kol/josep-tabernero/profile.json"},{"name":"Jaffer Ajani","slug":"jaffer-ajani","institution":"The University of Texas MD Anderson Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/jaffer-ajani","json_url":"https://www.findmykol.com/kol/jaffer-ajani/profile.json"},{"name":"Charles Fuchs","slug":"charles-fuchs","institution":"Tubulis GmbH","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/charles-fuchs","json_url":"https://www.findmykol.com/kol/charles-fuchs/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":5,"payments":45}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-27"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-27"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 to 2025","collected_at":"2026-10-27"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}